Glenmark Life Sciences Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Get Glenmark Life Sciences Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
quick-summary-circle
GLS

Click to see a quick summary and important updates about this stock!Dismiss

Glenmark Life Sciences Ltd.

BSE: 543322, NSE: GLS

  • Market Capitalisation market-capitalisation-info ₹5,086 Cr
  • 12 Month Earnings monthly-earning ₹420 Cr
  • Price to Earnings price-to-earning 12.12

₹414.55

As on 23-Mar-2023 09:19 IST

up-down-arrow ₹-0.40 • -0.10%

  • Prev Close info

    ₹414.95

  • Day's Openinfo

    ₹416.20

  • Today's Highinfo

    ₹416.20

  • Today's Lowinfo

    ₹411.95

  • Today's Volumeinfo

    6,738

Stock Performance
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Glenmark Life Sciences
-1.33 10.68 -1.03 -9.21 -- -- --
S&P BSE Healthcare
-6.10 -1.62 -8.14 -10.48 21.73 10.21 10.52
S&P BSE Small Cap
-6.04 -1.56 -4.37 -2.41 39.03 9.76 16.76
As on 23-Mar-2023
2022
Glenmark Life Sciences
-33.42
S&P BSE Small Cap
-1.80
S&P BSE Healthcare
-12.10

Valuation
Stock
Peer Median

Growth & Efficiency
Stock
Peer Median

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

View Details arrow

Peer Comparison

search
search
search
search
    Comparison Details arrow

    Valuation Chart of Glenmark Life Sciences Ltd.

        Financials

        View Details arrow

        Shareholding Pattern

        View Details arrow

        News & Analysis of Glenmark Life Sciences Ltd.

        ipo-update-glenmark-life-sciences

        IPO update: Glenmark Life Sciences

        By Danish Khanna

        glenmark-life-sciences-ipo-information-analysis

        Glenmark Life Sciences IPO: Information analysis

        By Rajan Gulati and Arul Selvan

        All News arrow

        Incorporated

        2011

        Chairman

        Glenn Saldanha

        Managing Director

        Yasir Rawjee

        Group

        Glenmark

        Headquarters

        Solapur, Maharashtra

        Website

        www.glenmarklifesciences.com
        More Details arrow
        Edit peer-selector-edit

        Key Facts

        • Market cap market-cap-information ₹5,086.10 Cr
        • Revenue (TTM)revenue-information ₹2,053.96 Cr
        • Earnings (TTM) earning-information ₹419.50 Cr
        • Cash date-information ₹364.56 Cr
        • Total Debt info ₹0.00 Cr
        • Promoters' ownership promoters_ownership 82.85%
        • Liquidity liquidity High
        • 52 Week range week-range ₹370.00 - 534.00
        • Face value face-value ₹2.00
        • Shares outstanding share-outstanding 12,25,27,172
        • 5 Years Aggregate:

          CFO: ₹1,190.58 Cr

          EBITDA: ₹1,926.26 Cr

          Net Profit: ₹1,278.56 Cr

        About The Company

        • Business Manufacture of pharmaceuticals, medicinal chemical and botanical products
        • Incorporated 2011
        • Chairman Glenn Saldanha
        • Managing Director Yasir Rawjee
        • Group Glenmark
        • Listing key-listing BSE: 543322, NSE: GLS
        • Country India
        • Headquarters headquarters Solapur, Maharashtra
        • Website website www.glenmarklifesciences.com
        Add Portfolio by-stock Add to watchlist watchlist-stock-modal Share Download Stock Report
        Portfolio stock-portfolio Watchlist watchlist-stock-modal share-fund-icon Download Stock Report
        Portfolio stock-investment Watchlist add-watchlist-icon share-fund-plan-icon